id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-4750-0021,FDA,FDA-2015-D-4750,The ‘‘Deemed to be a License’’ Provision of the BPCI Act: Questions and Answers; Draft Guidance for Industry; Availability; Request for Comments on Preliminary List of Affected Applications,Notice,Notice of Availability,2018-12-12T05:00:00Z,2018,12,2018-12-12T05:00:00Z,2019-02-12T04:59:59Z,2024-11-12T22:51:55Z,2018-26855,1,0,0900006483987c31
FDA-2015-D-4750-0022,FDA,FDA-2015-D-4750,"Draft Guidance for Industry The ""Deemed to be a License"" Provision of the BPCI Act Questions and Answers Guidance for Industry",Other,Guidance,2018-12-12T05:00:00Z,2018,12,2018-12-12T05:00:00Z,2019-02-12T04:59:59Z,2024-11-12T22:52:01Z,,1,0,0900006483988ea0
FDA-2015-D-4750-0020,FDA,FDA-2015-D-4750,"Interpretation of the ‘‘Deemed To Be a License’’ Provision of the Biologics
Price Competition and Innovation Act of 2009; Guidance for Industry;
Availability",Notice,Notice of Availability,2018-12-12T05:00:00Z,2018,12,2018-12-12T05:00:00Z,,2018-12-12T15:17:09Z,2018-26854,0,0,0900006483987aea
FDA-2015-D-4750-0023,FDA,FDA-2015-D-4750,01-Final Guidance for Industry Interpretation of the Deemed to be a License Provision of the Biologics Price Competition and Innovation Act of 2009,Other,Guidance,2018-12-12T05:00:00Z,2018,12,2018-12-12T05:00:00Z,,2024-11-12T22:53:33Z,,1,0,0900006483988e9e
FDA-2015-D-4750-0019,FDA,FDA-2015-D-4750,Memorandum of Meeting with Mylan,Other,Memorandum,2018-08-31T04:00:00Z,2018,8,2018-08-31T04:00:00Z,,2018-08-31T16:17:36Z,,0,0,09000064836875b1